tiprankstipranks
Advertisement
Advertisement

COGT Stock Latest News

Cogent Biosciences price target raised to $55 from $52 at H.C. Wainwright
The FlyCogent Biosciences price target raised to $55 from $52 at H.C. Wainwright
4d ago
COGT
Cogent Biosciences announces preclinical data from KRAS, ErbB2 programs
PremiumThe Fly
Cogent Biosciences announces preclinical data from KRAS, ErbB2 programs
24d ago
COGT
Bezuclastinib’s Strong Phase 3 GIST Data and NDA Catalyst Support Buy Rating and $52 Target
PremiumRatings
Bezuclastinib’s Strong Phase 3 GIST Data and NDA Catalyst Support Buy Rating and $52 Target
1M ago
COGT
Cogent Biosciences submits bezuclastinib new drug application to the FDA
PremiumThe Fly
Cogent Biosciences submits bezuclastinib new drug application to the FDA
1M ago
COGT
Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers
PremiumCompany Announcements
Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers
1M ago
COGT
Cogent Biosciences assumed with a Buy at Jefferies
PremiumThe FlyCogent Biosciences assumed with a Buy at Jefferies
2M ago
COGT
Cogent Biosciences: FDA accepts NDA for bzuclastinib in NonAdvSM
Premium
The Fly
Cogent Biosciences: FDA accepts NDA for bzuclastinib in NonAdvSM
2M ago
COGT
Cogent announces additional results from SUMMIT trial of bezuclastinib
Premium
The Fly
Cogent announces additional results from SUMMIT trial of bezuclastinib
2M ago
COGT
Cogent Biosciences price target raised to $35 from $34 at Baird
PremiumThe Fly
Cogent Biosciences price target raised to $35 from $34 at Baird
3M ago
COGT
Buy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
PremiumRatings
Buy Rating Backed by Bezuclastinib’s Late-Stage Catalysts, Dual-Launch Potential, and Differentiated Profile in GIST and SM
3M ago
COGT
Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
PremiumThe Fly
Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
3M ago
COGT
Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
PremiumCompany Announcements
Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
3M ago
COGT
Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year
PremiumThe FlyCogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year
3M ago
COGT
Cogent Biosciences sees cash runway into 2028
Premium
The Fly
Cogent Biosciences sees cash runway into 2028
3M ago
COGT
Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target
Premium
Ratings
Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target
3M ago
COGT
Cogent Biosciences announcse U.S. BTD for bezuclastinib
PremiumThe Fly
Cogent Biosciences announcse U.S. BTD for bezuclastinib
3M ago
COGT
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
PremiumCompany Announcements
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial
4M ago
COGT
Cogent to initiate New Drug Application submission for bezuclastinib
PremiumThe Fly
Cogent to initiate New Drug Application submission for bezuclastinib
4M ago
COGT
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Multiple 2026 NDA Filings Underpin Reiterated Buy and $52 Target
PremiumRatings
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Multiple 2026 NDA Filings Underpin Reiterated Buy and $52 Target
4M ago
COGT
Cogent Biosciences announces anticipated 2026 commercial, clinical milestones
PremiumThe FlyCogent Biosciences announces anticipated 2026 commercial, clinical milestones
4M ago
COGT
Aligos Therapeutics initiated with a Buy at UBS
Premium
The Fly
Aligos Therapeutics initiated with a Buy at UBS
4M ago
IVA
KOD
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Favorable FDA Outlook Underpin Upgraded $52 Buy Rating
Premium
Ratings
Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Favorable FDA Outlook Underpin Upgraded $52 Buy Rating
4M ago
COGT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >